DOI: 10.6084/m9.figshare.27144087.v1
title: Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients

description: <b>Aim:</b> Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity. <b>Methods:</b> PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI). <b>Results:</b> 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33–0.82); <i>p</i> = 0.005; I<sup>2</sup>= 32%], HF hospitalization [RR = 0.20 (0.04–1.02); <i>p</i> = 0.05; I<sup>2</sup>= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20–1.16); <i>p</i> = 0.11, I<sup>2</sup>= 0%]. <b>Conclusion:</b> SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment. This article explores the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a solution for reducing anthracycline-induced cardiotoxicity. Anthracycline is an established subclass of chemotherapeutic drugs which has been known to cause harm to the heart. The study, conducted a systematic search of PubMed and Google Scholar up until September 2023, assessing the effects of SGLT2i on overall mortality and cardiovascular events in cancer patients, regardless of the presence or absence of diabetes mellitus and the effectiveness of SGLT2i as a cardiotoxic therapy in cancer patients. The analysis of studies involving 2817 patients showed findings indicating that giving SGLT2i could lower the chances of anthracycline-induced heart problems in cancer patients undergoing treatment. The findings showed a striking decrease in hospitalization due to heart failure and overall mortality whereas the findings for the effect of SGLT2i on incidence of heart failure were insignificant. The encouraging outcomes offer valuable insights that could help enhance the outlook and chances of survival for individuals with cancer. These findings indicate that SGLT2i notably reduces the risk of death and cardiovascular issues, like being hospitalized due to heart failure, in cancer patients undergoing anthracycline treatment. This has significant implications for how doctors might treat cancer patients in practice. Including SGLT2i in the treatment plan could improve the survival prospects of these patients, offering a promising advancement in handling anthracycline-induced heart issues with side effects that can be managed. This meta-analysis assesses the cardio-protective effects of sodium-glucose transporter-2 inhibitor (SGLT2i) in cancer patients undergoing anthracycline therapy. The systematic review identified 3 cohort studies. Using a random-effects model, data for all outcomes of interest pooled risk ratio (RR) and hazard ratio (HR) at 95% confidence interval (CI) for this analysis. The pooled results showed a significant reduction in overall mortality and heart failure hospitalization in patients treated with SGLT2i compared with non-SGLT2i.